Aclaris Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Aclaris TherapeuticsDie Umsatzerlöse des Unternehmens werden voraussichtlich um 3.1% pro Jahr zurückgehen, während die jährlichen Gewinne voraussichtlich um 10.6% pro Jahr wachsen werden. Der Gewinn pro Aktie wird voraussichtlich um 17.1% pro Jahr wachsen.

Wichtige Informationen

10.6%

Wachstumsrate der Gewinne

17.1%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	-3.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	10 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Mar 01

Recent updates

We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

May 03

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Mar 07

Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Mar 01

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 19

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 11

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Nov 03

Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

Aug 10

What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Aug 08

Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Jun 06

We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Apr 07

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Dec 21

Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions

Oct 06

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aug 26

Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata

Aug 25

Aclaris Therapeutics gets a new COO

Aug 01

Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

May 28

Shareholders Will Probably Not Have Any Issues With Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Compensation

May 28

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ACRS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	8	-54	-39	-12	5
12/31/2025	11	-50	-48	-11	9
12/31/2024	11	-53	-56	-22	9
3/31/2024	31	-77	-74	-73	N/A
12/31/2023	31	-88	-80	-78	N/A
9/30/2023	21	-115	-92	-91	N/A
6/30/2023	31	-105	-75	-74	N/A
3/31/2023	31	-96	-74	-73	N/A
12/31/2022	30	-87	-68	-68	N/A
9/30/2022	24	-82	-66	-66	N/A
6/30/2022	6	-83	-69	-68	N/A
3/31/2022	6	-81	-61	-61	N/A
12/31/2021	7	-91	-52	-52	N/A
9/30/2021	7	-82	-44	-44	N/A
6/30/2021	7	-71	-46	-45	N/A
3/31/2021	7	-65	-44	-44	N/A
12/31/2020	6	-51	-39	-39	N/A
9/30/2020	6	-57	-51	-50	N/A
6/30/2020	6	-69	-63	-61	N/A
3/31/2020	4	-102	-73	-72	N/A
12/31/2019	4	-114	-98	-96	N/A
9/30/2019	5	-118	-105	-103	N/A
6/30/2019	5	-115	-111	-110	N/A
3/31/2019	6	-79	-112	-110	N/A
12/31/2018	6	-82	-102	-101	N/A
9/30/2018	5	-81	-94	-92	N/A
6/30/2018	5	-79	-77	-76	N/A
3/31/2018	3	-86	-65	-64	N/A
12/31/2017	2	-50	N/A	-55	N/A
9/30/2017	1	-57	N/A	-45	N/A
6/30/2017	N/A	-50	N/A	-41	N/A
3/31/2017	N/A	-48	N/A	-40	N/A
12/31/2016	N/A	-48	N/A	-35	N/A
9/30/2016	N/A	-42	N/A	-31	N/A
6/30/2016	N/A	-42	N/A	-31	N/A
3/31/2016	N/A	-33	N/A	-24	N/A
12/31/2015	N/A	-23	N/A	-20	N/A
9/30/2015	N/A	-21	N/A	-19	N/A
6/30/2015	N/A	-13	N/A	-10	N/A
3/31/2015	N/A	-12	N/A	-9	N/A
12/31/2014	N/A	-11	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ACRS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ACRS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ACRS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ACRSDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-3.1% pro Jahr).

Hohe Wachstumseinnahmen: ACRSDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-3.1% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ACRS in 3 Jahren voraussichtlich hoch sein wird

Aclaris Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 37%

Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Price target decreased by 9.5% to US$6.17

Price target decreased by 10% to US$6.81

Price target decreased by 52% to US$14.38

Consensus revenue estimates increase by 137%

Recent updates

Consensus revenue estimates increase by 37%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Aclaris Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Aclaris Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Aclaris Therapeutics, Inc. Announces Intangible Asset Impairment for the Three Months Ended December 31, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Aclaris Therapeutics, Inc. Announces Termination of Employment of Gail Cawkwell as Chief Medical Officer

Price target decreased by 9.5% to US$6.17

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Insufficient new directors

Aclaris Therapeutics, Inc. Announces Douglas Manion Steps Down as President and Member of the Board of Directors

Aclaris Therapeutics, Inc. Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Price target decreased by 10% to US$6.81

Price target decreased by 52% to US$14.38

Aclaris Therapeutics, Inc. Announces Top-Line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

New major risk - Share price stability

Consensus revenue estimates increase by 137%

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Chief Financial Officer recently bought US$75k worth of stock

Chief Business Officer recently bought US$100k worth of stock

Consensus revenue estimates decrease by 10%

Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

New major risk - Financial position

What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Consensus revenue estimates increase by 18%, EPS downgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Price target decreased by 10.0% to US$29.11

Co-Founder & Chairman recently sold US$510k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Chief Scientific Officer notifies of intention to sell stock

Price target decreased by 8.1% to US$32.00

Chief Business Officer recently sold US$59k worth of stock

Price target decreased by 8.1% to US$32.00

Co-Founder notifies of intention to sell stock

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Price target decreased to US$32.25

Aclaris Therapeutics, Inc. Announces Chief Financial Officer Changes

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Chief Scientific Officer notifies of intention to sell stock

Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Aclaris Therapeutics, Inc. Announces Executive Changes

Aclaris Therapeutics gets a new COO

Aclaris Therapeutics, Inc. Appoints Gail Cawkwell as Chief Medical Officer

Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

Consensus forecasts updated

Aclaris Therapeutics, Inc. Appoints Ian Anderson as Executive Vice President, Translational Research & Development

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Co-Founder notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

Aclaris Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Chief Medical Officer notifies of intention to sell stock

Co-Founder recently sold US$896k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Aclaris Therapeutics, Inc. Names James Loerop as Chief Business Officer, Effective January 31, 2022